TY - JOUR
T1 - Intracameral recombinant tissue plasminogen activator (r-tPA) for refractory toxic anterior segment syndrome
AU - Dotan, Assaf
AU - Kaiserman, Igor
AU - Kremer, Israel
AU - Ehrlich, Rita
AU - Bahar, Irit
PY - 2014/2
Y1 - 2014/2
N2 - Aims To investigate the therapeutic effect of recombinant tissue plasminogen activator (r-tPA) in patients with refractory toxic anterior chamber segment syndrome after cataract surgery with posterior chamber intraocular lens implantation. Methods This prospective cohort study was performed from May 2010 to November 2011 at a tertiary university-based medical centre. Forty patients (40 eyes) with an anterior chamber fibrin reaction after cataract surgery were treated with intracameral injection of r-tPA (25 mg/0.1 mL) following failure to respond to conventional treatment with intensive topical and subconjunctival steroids. Outcome measures were bestcorrected visual acuity, clearance/recurrence of the fibrin reaction and complications. Corneal endothelial cell counts were evaluated before and after r-tPA injection (n=6). Results Intracameral r-tPA injection was administered 10-49 days after cataract surgery; mean was 20.3 ±9.6 days after surgery. At 1 day after treatment, complete clearance of the fibrin reaction was observed in 32 patients (80%) and partial clearance in 8 (20%). At the 1-month evaluation, the reaction had completely resolved in 95% of patients. Mean visual acuity improved from 0.61±0.38 logMAR before treatment to 0.45±0.37 logMAR 1 month later ( p=0.06). There were no statistically significant differences in improvement in visual acuity and fibrinolysis rate by time of r-tPA injection after surgery (10-15 days, n=16 vs 16-49 days, n=24). There were no cases of increased intraocular pressure or endophthalmitis following the procedure. Conclusions Intracameral injection of 25 mg r-tPA is safe and effective for the treatment of refractory fibrin reaction after cataract surgery.
AB - Aims To investigate the therapeutic effect of recombinant tissue plasminogen activator (r-tPA) in patients with refractory toxic anterior chamber segment syndrome after cataract surgery with posterior chamber intraocular lens implantation. Methods This prospective cohort study was performed from May 2010 to November 2011 at a tertiary university-based medical centre. Forty patients (40 eyes) with an anterior chamber fibrin reaction after cataract surgery were treated with intracameral injection of r-tPA (25 mg/0.1 mL) following failure to respond to conventional treatment with intensive topical and subconjunctival steroids. Outcome measures were bestcorrected visual acuity, clearance/recurrence of the fibrin reaction and complications. Corneal endothelial cell counts were evaluated before and after r-tPA injection (n=6). Results Intracameral r-tPA injection was administered 10-49 days after cataract surgery; mean was 20.3 ±9.6 days after surgery. At 1 day after treatment, complete clearance of the fibrin reaction was observed in 32 patients (80%) and partial clearance in 8 (20%). At the 1-month evaluation, the reaction had completely resolved in 95% of patients. Mean visual acuity improved from 0.61±0.38 logMAR before treatment to 0.45±0.37 logMAR 1 month later ( p=0.06). There were no statistically significant differences in improvement in visual acuity and fibrinolysis rate by time of r-tPA injection after surgery (10-15 days, n=16 vs 16-49 days, n=24). There were no cases of increased intraocular pressure or endophthalmitis following the procedure. Conclusions Intracameral injection of 25 mg r-tPA is safe and effective for the treatment of refractory fibrin reaction after cataract surgery.
UR - http://www.scopus.com/inward/record.url?scp=84892565214&partnerID=8YFLogxK
U2 - 10.1136/bjophthalmol-2013-304294
DO - 10.1136/bjophthalmol-2013-304294
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
AN - SCOPUS:84892565214
SN - 0007-1161
VL - 98
SP - 252
EP - 255
JO - British Journal of Ophthalmology
JF - British Journal of Ophthalmology
IS - 2
ER -